An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study-Reference-Cited by-同舟云学术

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Published:2022-10-05 Issue:11 Volume:15 Page:2663-2672
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Kallend David¹,Mason Jay²^ORCID,Smith Patrick F.³,Koren Michael J.⁴⁵,Stoekenbroek Robert⁶,He YanLing⁷,Wijngaard Peter⁸

Affiliation:

1. Former Employee of The Medicines Company (Schweiz) GmbH Zurich Switzerland

2. Department of Internal Medicine, University of Utah School of Medicine Salt Lake City Utah USA

3. Certara, Inc. Parsippany New Jersey USA

4. First Coast Heart & Vascular Center Jacksonville Florida USA

5. Jacksonville Center for Clinical Research Jacksonville Florida USA

6. Former Employee of the Medicines Company Parsippany New Jersey USA

7. Novartis Institutes for BioMedical Research, Inc. Cambridge Massachusetts USA

8. Former Employee of Novartis Pharmaceuticals Corporation East Hanover New Jersey USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13391

Reference18 articles.

1. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

2. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

3. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels

4. Safety and efficacy of inclisiran in patients with heterozygous familial hypercholesterolemia – results from the phase 3 ORION‐9 trial;Raal FJ;Circulation,2019

5. Safety and efficacy of inclisiran in patients with ASCVD and elevated LDL cholesterol – results from the phase 3 ORION‐10 trial;Wright RS;Circulation,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on inclisiran for the treatment of elevated LDL cholesterol;Expert Opinion on Pharmacotherapy;2024-03-03

2. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

3. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients;Expert Opinion on Drug Safety;2023-12-08

4. Updates in Small Interfering RNA for the Treatment of Dyslipidemias;Current Atherosclerosis Reports;2023-10-04

5. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease;Cardiovascular Diabetology;2023-01-30